Basilea Pharmaceutica
Basilea Pharmaceutica sponsors 21 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 14 completed. 5 of these trials are in Phase 3-4 (later-stage) and 16 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pharmacokinetics, with 2 trials.
Trial Pipeline
21 total, page 1 of 1
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.
NCT06925321
Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination
NCT06733675
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
NCT05421858
Plasma and Intrapulmonary Pharmacokinetics of Ceftibuten and Ledaborbactam in Healthy Male and Female Participants 18 to ≤55 Years of Age
NCT06665555
Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age
NCT05856227
A Clinical Trial of the Study Medicine (Called Fosmanogepix) in Participants With Varying Degrees of Hepatic Function.
NCT05582187
Ceftibuten/VNRX-7145 in Participants With Varying Degrees of Renal Function
NCT05488678
Food Effect on Ceftibuten/VNRX-7145 in Healthy Participants
NCT05527834
A Bioequivalence Study of APX001 High-load and Low-load Tablets
NCT05491733
Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma
NCT04604132
VNRX-7145 SAD/MAD Safety and PK in Healthy Adult Volunteers
NCT04243863
Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds
NCT04240886
Derazantinib and Atezolizumab in Patients With Urothelial Cancer
NCT04045613
An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia
NCT03604705
Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia
NCT03138733
Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections
NCT03137173
Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
NCT03250299
Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
NCT03230318
Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics
NCT02527681
Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
NCT01752920
Open Label Study of Ceftobiprole to Evaluate Pharmacokinetics in Adults Hospitalized in the ICU
NCT00770978
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 13 |
| Phase 2 | 3 |
| Phase 3 | 5 |
What the Pipeline for Basilea Pharmaceutica Shows
According to the ClinicalTrials.gov registry, Basilea Pharmaceutica is linked to 21 US clinical trials across every stage of research activity. Of those, 3 studies are currently recruiting, about 14% of the sponsor's indexed portfolio, and 14 are already marked complete, representing roughly 67% of the total.
The phase mix for Basilea Pharmaceutica reports 5 late-stage studies (Phase 3 and Phase 4 combined) and 16 earlier-phase studies (Phase 1 and Phase 2).
The top therapeutic focus area indexed for Basilea Pharmaceutica is Pharmacokinetics with 2 linked trials, and 9 other condition areas appear in the top list above.
How to read these pipeline numbers
Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work, safety, dosing, and early signal detection, and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice, verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.